Researchers at Heinrich-Heine-University Düsseldorf, led by Dennis Sohn and colleagues, report that pediatric medulloblastoma cells carrying functional, wild-type p53 do not simply die when bombarded with gamma irradiation. Instead, many of them enter senescence, a terminal and stable arrest of the cell cycle. These zombie-like cells stop dividing but refuse to die, lingering in the tissue for weeks. Crucially, the team showed that these irradiated, senescent tumor cells can then be selectively wiped out with senolytic drugs—compounds designed to eliminate senescent cells. The finding opens a potential two-step strategy: radiation first drives susceptible tumor cells into senescence, and senolytics then clear them away.

The study compared two SHH-activated medulloblastoma cell lines with fundamentally different genetic backgrounds. ONS76 cells carry wild-type p53, the master tumor suppressor that decides a cell’s fate after catastrophic DNA damage. UW228-3 cells carry a mutated, dysfunctional p53. When both lines were exposed to a 20 Gy dose of gamma irradiation, their responses diverged dramatically. UW228-3 cells detached from the culture dish and degraded completely within three to seven days. ONS76 cells, by contrast, remained attached for more than fifty days, flattening out and swelling enormously in both cell body and nucleus—classic hallmarks of senescence.

The molecular evidence followed the morphology. Irradiated ONS76 cells showed a dose-dependent stabilization of p53 and a strong increase in p21, the cyclin-dependent kinase inhibitor encoded by the CDKN1A gene that enforces the senescence arrest. They also accumulated senescence-associated beta-galactosidase activity, a lysosomal enzyme widely used as a senescence marker, and built up lipofuscin, the pigment-like cellular debris characteristic of aged or senescent cells. When the researchers knocked down p53 or p21 using siRNAs, the senescence program collapsed: far fewer cells became senescent and substantially more died instead. This established that radiation-induced senescence in these cells is strictly p53/p21-dependent.

The p53-mutated UW228-3 cells told the opposite story. They showed only a faint, transient rise in beta-galactosidase activity and never developed senescent morphology. Instead, measurements of lactate dehydrogenase release—a marker of plasma membrane destruction—and of DEVDase-like caspase activity revealed that they died by apoptosis, the controlled self-destruction pathway. A pan-caspase inhibitor, q-VD-OPh, completely abolished this cell death while leaving senescence untouched in the wild-type line. The team also employed a recently developed fluorescent lipofuscin binder, GLF16, alongside the amine-reactive viability dye Zombie-violet, allowing simultaneous flow cytometric quantification of senescent and dead cells with sharper discrimination than traditional staining.

The researchers then turned to c-Myc, a proto-oncogene that serves as a crucial negative prognostic factor in medulloblastoma and is known to antagonize p21. Using engineered ONS76 and UW228-3 lines that constitutively overexpress c-Myc, they found that the oncogene tipped the balance away from senescence. In irradiated ONS76/c-Myc cells, p21 protein levels dropped—though p21 mRNA levels did not, indicating that c-Myc interferes with p21 protein production or stability rather than its transcription. Fewer cells adopted senescent morphology, and more cells died, a death that q-VD-OPh could block even though it was not accompanied by elevated caspase activity. Notably, this c-Myc effect operated independently of p53 status. The senescent population in c-Myc-overexpressing cells also proved far more resistant to senolytic treatment, underscoring how oncogene dosage can shape therapeutic vulnerability.

The therapeutic payoff came in the final set of experiments. Seven days after irradiation, when the ONS76 cultures had become fully senescent, the researchers treated them with four senolytic compounds: the BCL-2 family inhibitors Navitoclax and Venetoclax, and the PI3K inhibitors PX-866 and BAY 80-6946 (Copanlisib), the latter already FDA-approved. All four killed the senescent cells in a dose-dependent manner. Navitoclax, however, also eliminated proliferating cells at the highest concentration tested, 30 µM—a reminder of the well-known toxicity problem that has complicated its clinical use, since healthy non-senescent cells are targeted at higher doses. The PI3K inhibitors, by contrast, showed a cleaner specificity for the senescent population.

The clinical logic behind this approach is compelling. Medulloblastoma is unusual among cancers in that relatively few tumors harbor p53 mutations, and in the SHH-activated subtype, p53 status actually defines two distinct risk groups: p53-mutated tumors carry a five-year overall survival of roughly 41 percent and are classified as high risk, while p53 wild-type tumors fare far better at about 81 percent. The new findings suggest that these two groups respond to radiotherapy in mechanistically different ways—senescence in the wild-type setting, apoptosis in the mutated one—a distinction invisible to standard proliferation-based cytotoxicity assays. Senolytic combination therapy would therefore primarily apply to the intermediate-risk, p53 wild-type group, where it could potentially improve outcomes further while reducing the radiation dose needed for tumor control.

The broader context strengthens the case. Senescent cells are not inert; they secrete a cocktail of cytokines and chemokines known as the senescence-associated secretory phenotype, or SASP, which drives chronic tissue microinflammation and can support tumor relapse. Craniospinal irradiation is associated with accelerated brain aging in survivors, and studies in glioblastoma have already shown that eliminating therapy-induced senescent cells with Navitoclax attenuates recurrence. Mouse studies of whole-brain irradiation likewise suggest that senolytic clearance protects cognitive function and the blood-brain barrier. Because senescence can be triggered at lower radiation doses than outright cell death, pairing senolytics with craniospinal irradiation might one day allow clinicians to cure tumors with less radiation exposure while simultaneously mopping up the senescent cells that radiation leaves behind.

Important caveats remain. The entire study was conducted in cell lines rather than animal models or patients, and the exact nature of the c-Myc-driven, caspase-inhibitable cell death observed in the overexpressing cells is still unclear. The authors themselves note that it would be intriguing to test whether JQ1, a bromodomain inhibitor that suppresses c-Myc signaling, could push c-Myc-high, p53 wild-type medulloblastoma cells back into a senescence-permissive state and thereby restore their susceptibility to senolytics. Still, the work is the first to document radiation-induced senescence in medulloblastoma cells and to demonstrate that these cells can be eliminated with existing senolytic drugs. If the strategy survives translation into preclinical models, it could reshape how one of pediatric oncology’s most grueling treatments is delivered—turning the very cells that radiation strands between life and death into targets for a second, cleaner strike.

Subject of Research: Radiation-induced cellular senescence in pediatric medulloblastoma and its targeting by senolytic drugs

Article Title: p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances

Article References: Sonntag, J., Preugschas, R.-L., Jazmati, D., Qin, N., Neuwahl, J., Matuschek, C., Remke, M., Budach, W., Hörner-Rieber, J., & Sohn, D. (2026). p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances. Cell Death Discovery, 12(1), Article 410. https://doi.org/10.1038/s41420-026-03404-4

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03404-4

Keywords: medulloblastoma, senescence, senolytics, p53, c-Myc, p21, gamma irradiation, craniospinal irradiation, Navitoclax, PI3K inhibitors, SASP, pediatric brain tumor

The 2021 fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System formally recognizes four spinal entities: spinal ependymoma, spinal ependymoma with MYCN amplification, spinal subependymoma, and spinal myxopapillary ependymoma. Diagnosis is no longer a matter of histology alone. Instead, clinicians must integrate the anatomical compartment, the microscopic appearance of the tumor, and its molecular signature, most often assessed through DNA methylation profiling. That shift matters because the subtypes behave very differently. Myxopapillary ependymomas, for example, were upgraded from grade 1 to grade 2 after clinicians realized that incompletely removed tumors, once watched passively, could recur with spread through the subarachnoid space, a complication that typically forces craniospinal irradiation and carries substantial morbidity.

Pediatric-specific molecular data are beginning to sharpen this picture. In the HIT-MED spinal cohort of 83 patients aged 22 or younger, methylation classes broke down as 63 percent myxopapillary, 33 percent conventional spinal ependymoma, and 4 percent MYCN-amplified. Strikingly, within this pediatric population the molecular class did not clearly separate risk levels between the two most common groups; instead, the extent of surgical resection and the WHO grade remained the dominant determinants of progression-free survival. Molecular profiling, in other words, refines biological classification, but for most children the scalpel and the microscope still tell the most important part of the story.

The exception is the MYCN-amplified subtype, which the review describes as one of the most aggressive entities in the entire ependymoma family. These tumors tend to relapse early, typically within about 2.3 years, and can prove fatal despite aggressive multimodal treatment regardless of the age at diagnosis. Identifying MYCN amplification therefore has immediate clinical consequences: high-risk counseling, intensified craniospinal surveillance, and consideration of clinical trials or novel therapeutics. The authors argue that every spinal ependymoma specimen should undergo reflex testing for MYCN amplification alongside formal WHO 2021 grading and, where available, methylation profiling. Even the ostensibly indolent myxopapillary tumors carry sobering long-term statistics, with a 10-year progression-free survival of roughly 59 percent in mixed-age datasets, and within pediatric myxopapillary disease, methylation subtype B showed a trend toward better five-year progression-free survival than subtype A, 86 percent versus 56 percent, though the difference has not reached statistical significance.

Clinically, these tumors announce themselves quietly. Adults and older children typically report progressive sensory disturbance, gait imbalance, weakness, axial back pain, or radicular pain, and most patients are still ambulatory at diagnosis. The insidious tempo, however, often means the tumor has extended over multiple spinal segments by the time imaging is obtained. In preverbal children the presentation can be maddeningly nonspecific: torticollis, regression of motor milestones, refusal to walk or crawl, or simple irritability, signs easily misattributed to musculoskeletal or developmental causes. The review stresses that any suspicion demands gadolinium-enhanced MRI of the entire neuraxis, including the brain, because drop metastases occur in a minority of patients and missing them leads to under-staging and inadequate adjuvant planning.

On imaging, the intramedullary subtypes typically show symmetric cord expansion, well-demarcated margins, contrast enhancement, polar cysts, and syringomyelia in 40 to 70 percent of cases. A rim of hemosiderin at the tumor poles, the so-called cap sign, hints at a distinct gliotic plane that surgeons can exploit for dissection. MYCN amplification itself cannot be seen radiographically, but irregular margins, infiltrative extension, multifocal nodularity, or leptomeningeal enhancement should raise suspicion for high-risk molecular disease. Myxopapillary tumors behave differently, arising extramedullary at the filum terminale with a lobulated, avidly enhancing morphology that displaces rather than infiltrates neighboring nerve roots.

Surgery sits at the center of management, and the review frames every operative decision along three fronts: whether gross total resection is anatomically feasible, what functional neurological risks it carries, and what the biological risk of recurrence or dissemination happens to be. Gross total resection is the most consistent modifiable predictor of progression-free survival, with contemporary series reporting rates of roughly 72 to 83 percent. Continuous multimodal intraoperative neuromonitoring, combining somatosensory evoked potentials, transcranial motor evoked potentials, and D-wave recording, allows real-time assessment of the dorsal columns and corticospinal tract, and a sustained deterioration in motor potentials or a significant D-wave drop strongly predicts permanent motor deficit. When signals fail irreversibly, a deliberate subtotal resection may be the wiser course, and early postoperative MRI within 24 to 48 hours guides whether a second-look operation should precede any adjuvant therapy. For myxopapillary lesions, meticulous capsule preservation is paramount, because capsular violation is associated with local recurrence, cerebrospinal fluid dissemination, and the need for radiotherapy; en bloc resection is preferred when technically feasible.

In children, the spine itself becomes a battleground. Postoperative deformity is arguably the most important surgical morbidity in this population, and the data are stark: in one series of 161 children, 27 percent eventually required fusion, with risk rising sharply in those under 13, those with preoperative scoliosis, tumor-associated syrinx, thoracolumbar junction involvement, or each additional resection. Another study found deformity in 38 percent of children before surgery and 69 percent afterward, even when laminoplasty was used throughout, underscoring that tumor biology and preoperative status drive much of the risk. Neither laminoplasty nor laminectomy reliably prevents kyphosis, and instrumented fusion, while stabilizing, permanently sacrifices motion and growth potential and can degrade the quality of the lifelong surveillance MRI these patients need. Radiation adds its own age-dependent hazard: a comprehensive PENTEC review found clinically significant scoliosis at vertebral doses as low as 15 Gy in infants under two, with rates exceeding 30 percent above 20 Gy in children aged two to six, thresholds substantially below the 45 to 59.4 Gy focal doses typically prescribed.

Adjuvant therapy follows a risk-adapted logic. After gross total resection of a grade 2 spinal ependymoma, most contemporary evidence supports surveillance without routine radiotherapy, since a clear benefit has not been consistently demonstrated. After subtotal resection or biopsy, focal conformal radiotherapy is recommended because incomplete resection consistently predicts inferior progression-free survival. Grade 3 tumors receive focal radiotherapy regardless of resection extent, and craniospinal irradiation is considered when dissemination is present or suspected. For myxopapillary tumors the role of postoperative radiotherapy remains genuinely contested, with some retrospective series, including pediatric cohorts, suggesting improved control even after complete resection, particularly with dose escalation above 50.4 Gy or when high-risk features exist, while other adult-dominant datasets support observation alone. A recent multi-institutional pediatric and young adult series of high-risk myxopapillary disease reported five-year overall survival of 100 percent and progression-free survival of 60.8 percent, but patients still relapsed outside the treated field and intracranially, arguing for vigilance beyond the radiation volume rather than dose escalation alone. Chemotherapy, meanwhile, has no established frontline role; it is reserved for recurrent or disseminated disease, clinical trials, or as a deliberate strategy to defer radiotherapy in infants, an approach validated for intracranial ependymoma but never formally studied in the spine.

The review’s most candid contribution may be its systematic accounting of what medicine does not know. Nearly every management domain, from radiotherapy dosing and timing to the value of molecular stratification beyond MYCN, rests on adult or mixed-age retrospective cohorts, and no prospective pediatric-specific data address whether current thresholds should differ for a growing child. Local recurrence remains the dominant failure pattern even after complete resection, and craniospinal dissemination can appear years later, which is why the authors recommend lifelong MRI surveillance for every patient, with intensified brain and full-neuraxis imaging for those with dissemination or high-risk subtypes. For isolated recurrences, repeat maximal safe resection remains the mainstay, followed by focal radiotherapy in radiation-naive patients, though cumulative dose tolerance to the spinal cord and the specter of radiation-induced deformity weigh heavily in children who face a far longer horizon of potential exposure. The path forward, the authors conclude, requires prospective multicenter studies, validated molecular risk models, and novel systemic therapies for the aggressive subtypes, so that the next generation of children with spinal ependymoma can be treated on evidence of their own rather than borrowed from adults.

Subject of Research: Molecular classification and management of pediatric spinal ependymoma

Article Title: Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

Article References: Price, A. M., Fredricks, N. S., Koutsouras, G., Vallejo, F. A., Bonfield, C., Pastakia, D. J., Luo, L. Y., Boop, F., Ramaswamy, V., & Dewan, M. C. (2026). Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments). Journal of Neuro-Oncology, 180(1), Article 6. https://doi.org/10.1007/s11060-026-05816-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05816-9

Keywords: spinal ependymoma, pediatric neuro-oncology, MYCN amplification, myxopapillary ependymoma, WHO CNS5 classification, gross total resection, intraoperative neuromonitoring, adjuvant radiotherapy, spinal deformity, DNA methylation profiling, craniospinal irradiation, lifelong surveillance